Pitoiset Fabien, Vazquez Thomas, Bellier Bertrand
Department of Inflammation-Immunopathology-Biotherapy (I2B), Clinical Investigation Center for Biotherapies (CIC-BTi), Hôpital Pitié-Salpêtrière, Assistance Publique Hôpitaux de Paris (AP-HP), Paris, France.
Expert Rev Vaccines. 2015 Jul;14(7):913-5. doi: 10.1586/14760584.2015.1046440. Epub 2015 May 12.
The techniques to produce effective vaccines have evolved, and the early vaccines (live, inactivated, subunit...) are no longer considered as the most appropriate for new vaccine development. We question here what will be the future vaccines, and argue that virus-like particle (VLP)-based vaccines are promising candidates. In addition to being effective vaccines against analogous viruses from which they are derived, VLPs can also be used to present foreign epitopes to the immune system. The achievement of this strategy can be illustrated by the recent development of malaria candidate vaccine. We point out recent VLP-based vaccine developments and discuss future perspectives.
生产有效疫苗的技术已经发展，早期的疫苗（活疫苗、灭活疫苗、亚单位疫苗等）不再被认为是新疫苗开发的最合适选择。在此，我们探讨未来的疫苗会是什么样子，并认为基于病毒样颗粒（VLP）的疫苗是很有前景的候选者。除了作为针对其来源的类似病毒的有效疫苗外，VLP还可用于将外来表位呈递给免疫系统。疟疾候选疫苗的最新进展可以说明这一策略的成果。我们指出了最近基于VLP的疫苗进展，并讨论了未来的前景。
